Helen Kim elected to ImmunoCellular's board
This article was originally published in Scrip
ImmunoCellular Therapeutics has appointed Helen Kim to its board of directors, and chairperson of the company's product strategic committee. Ms Kim currently serves as a board member for Sunesis Pharmaceuticals, and chief business officer of NGM Biopharmaceuticals. She was previously president and CEO of Kosan Biosciences before its sale to Bristol-Myers Squibb.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.